PT2694546T - Moléculas de ligação biespecíficas que se ligam a vegf e ang2 - Google Patents

Moléculas de ligação biespecíficas que se ligam a vegf e ang2

Info

Publication number
PT2694546T
PT2694546T PT127112019T PT12711201T PT2694546T PT 2694546 T PT2694546 T PT 2694546T PT 127112019 T PT127112019 T PT 127112019T PT 12711201 T PT12711201 T PT 12711201T PT 2694546 T PT2694546 T PT 2694546T
Authority
PT
Portugal
Prior art keywords
binding
ang2
vegf
bispecific
binding molecules
Prior art date
Application number
PT127112019T
Other languages
English (en)
Inventor
Depla Erik
Buyse Marie-Ange
Gschwind Andreas
Georg Ott Rene
Boucneau Joachim
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45895502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2694546(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PT2694546T publication Critical patent/PT2694546T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT127112019T 2011-04-01 2012-03-30 Moléculas de ligação biespecíficas que se ligam a vegf e ang2 PT2694546T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11160921 2011-04-01

Publications (1)

Publication Number Publication Date
PT2694546T true PT2694546T (pt) 2016-12-28

Family

ID=45895502

Family Applications (1)

Application Number Title Priority Date Filing Date
PT127112019T PT2694546T (pt) 2011-04-01 2012-03-30 Moléculas de ligação biespecíficas que se ligam a vegf e ang2

Country Status (35)

Country Link
US (4) US9527925B2 (pt)
EP (2) EP3144322A3 (pt)
JP (2) JP6023786B2 (pt)
KR (1) KR101907572B1 (pt)
CN (2) CN105820243A (pt)
AP (1) AP2013007085A0 (pt)
AR (1) AR085984A1 (pt)
AU (2) AU2012237234B2 (pt)
BR (1) BR112013025304B1 (pt)
CA (1) CA2827817C (pt)
CL (1) CL2013002623A1 (pt)
CO (1) CO6801639A2 (pt)
CY (1) CY1118339T1 (pt)
DK (1) DK2694546T3 (pt)
EA (2) EA025148B1 (pt)
EC (1) ECSP13013001A (pt)
ES (1) ES2606302T3 (pt)
HK (2) HK1225400A1 (pt)
HR (1) HRP20161689T1 (pt)
HU (1) HUE030148T2 (pt)
IL (1) IL227936B (pt)
LT (1) LT2694546T (pt)
MA (1) MA34979B1 (pt)
MX (2) MX337543B (pt)
MY (1) MY171007A (pt)
PE (1) PE20140448A1 (pt)
PL (1) PL2694546T3 (pt)
PT (1) PT2694546T (pt)
RS (1) RS55361B1 (pt)
SG (2) SG10201602373TA (pt)
SI (1) SI2694546T1 (pt)
TN (1) TN2013000390A1 (pt)
UA (1) UA114707C2 (pt)
UY (1) UY33998A (pt)
WO (1) WO2012131078A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
MX350248B (es) * 2012-03-30 2017-08-31 Boehringer Ingelheim Int Moleculas de union a ang2.
RS62509B1 (sr) 2012-07-13 2021-11-30 Roche Glycart Ag Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti
CA2883880A1 (en) * 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents
BR112015006363A2 (pt) * 2012-09-28 2017-08-08 Boehringer Ingelheim Int combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
US10010626B2 (en) * 2015-01-16 2018-07-03 Immunwork Inc. Molecular constructs with targeting and effector moieties
AR103477A1 (es) 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2
CA2981103A1 (en) * 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
DK3277719T3 (da) 2015-03-31 2022-05-02 Sorriso Pharmaceuticals Inc Polypeptider
RU2749674C2 (ru) * 2015-07-29 2021-06-16 Аллерган, Инк. Антитела против ang-2, содержащие только тяжелую цепь
EP3334762A1 (en) * 2015-08-14 2018-06-20 Allergan, Inc. Heavy chain only antibodies to pdgf
TWI748962B (zh) * 2015-09-23 2021-12-11 美商建南德克公司 抗ｖｅｇｆ抗體之最佳化變異體
HUE057241T2 (hu) * 2015-11-13 2022-04-28 Ablynx Nv Javított, szérumalbumint kötõ immunoglobulin variábilis domének
MA43368B1 (fr) 2015-12-04 2020-09-30 Boehringer Ingelheim Int Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales
CA3034576A1 (en) * 2016-08-23 2018-03-01 Medimmune Limited Anti-vegf-a antibodies and uses thereof
AU2017315075B2 (en) * 2016-08-23 2020-10-01 Medimmune Limited Anti-VEGF-A and anti-ANG2 antibodies and uses thereof
EP4190318A1 (en) * 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
RU2648164C1 (ru) * 2016-12-19 2018-03-22 Федеральное государственное учреждение науки Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Селективный бифункциональный препарат на основе фрагментов одноцепочечных антител верблюжьих, нацеленный на опухолевые рецепторы cd47/erbb2, предназначенный для терапии злокачественных новообразований
WO2018114728A1 (en) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody
CN109071656B (zh) 2017-01-05 2021-05-18 璟尚生物制药公司 检查点调节物拮抗剂
AU2018276409A1 (en) 2017-05-31 2019-10-31 Boehringer Ingelheim International Gmbh Polypeptides antagonizing Wnt signaling in tumor cells
BR112019022074A2 (pt) * 2017-06-02 2020-05-12 Boehringer Ingelheim International Gmbh Terapia de combinação anticâncer
WO2019154776A1 (en) 2018-02-06 2019-08-15 F. Hoffmann-La Roche Ag Treatment of ophthalmologic diseases
US20220257600A1 (en) * 2018-06-20 2022-08-18 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
EP3814381A4 (en) 2018-06-29 2022-08-10 Gensun Biopharma Inc. TRI-SPECIFIC ANTAGONISTS
WO2020089051A1 (en) 2018-10-29 2020-05-07 F. Hoffmann-La Roche Ag Antibody formulation
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
EP3986931A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
AU2020294980A1 (en) 2019-06-21 2022-02-17 Sorriso Pharmaceuticals, Inc. Polypeptides
JP2022540571A (ja) 2019-06-28 2022-09-16 ゲンスン バイオファーマ、インコーポレーテッド 変異したＴＧＦβ１－ＲＩＩ細胞外ドメインおよび免疫グロブリン足場で構成される抗腫瘍アンタゴニスト
CN110452297B (zh) * 2019-09-03 2020-04-14 上海洛启生物医药技术有限公司 抗vegf单域抗体及其应用
US20230032087A1 (en) * 2019-12-11 2023-02-02 Cullinan Oncology, Inc. Anti-serum albumin antibodies
WO2021155151A1 (en) * 2020-01-29 2021-08-05 The Methodist Hospital System Multivalent ligands targeting cell surface receptors and force measurement platform for making the same
WO2021209458A1 (en) 2020-04-14 2021-10-21 Ares Trading S.A. Combination treatment of cancer
US20230242633A1 (en) 2020-07-07 2023-08-03 Kanaph Therapeutics Inc. Fusion protein including complement pathway inhibitor and angiogenesis inhibitor and use thereof
CN116507627A (zh) 2020-11-02 2023-07-28 勃林格殷格翰国际有限公司 作为egfr抑制剂的经取代1h-吡唑并[4,3-c]吡啶及衍生物
EP4019548A1 (en) * 2020-12-23 2022-06-29 Vrije Universiteit Brussel Anti lag3 vhhs and their use
US20240279324A1 (en) 2021-06-03 2024-08-22 Gensun Biopharma Inc. Multispecific antagonists
AU2022287100A1 (en) * 2021-06-04 2024-01-25 Innovent Biologics (Suzhou) Co., Ltd. Bispecific binding molecule binding vegf and ang2 and use thereof
CN118043350A (zh) * 2021-08-13 2024-05-14 信达生物制药(苏州)有限公司 抗vegf a和vegf c双特异性抗体及其用途
CA3231417A1 (en) * 2021-09-10 2023-03-16 Jian Shi Anti-ang2 antibody, preparation method therefor, and application thereof
CU20210101A7 (es) * 2021-12-15 2023-07-12 Ct Ingenieria Genetica Biotecnologia Polipéptidos que se unen a factores de crecimiento proangiogénicos
KR20230105972A (ko) 2022-01-05 2023-07-12 주식회사 카나프테라퓨틱스 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
WO2024055996A1 (zh) * 2022-09-14 2024-03-21 寻济生物科技（北京）有限公司 一种抗vegfa抗体或其抗原结合片段及其应用
WO2024114799A1 (zh) * 2022-12-01 2024-06-06 信达生物制药(苏州)有限公司 三特异性融合蛋白及其用途
TW202426052A (zh) * 2022-12-01 2024-07-01 大陸商信達生物製藥（蘇州）有限公司 包含結合ｖｅｇｆ和ａｎｇ２的雙特異性結合分子的製劑以及其用途
WO2024178730A1 (zh) * 2023-03-02 2024-09-06 清华大学 用于抑制脉络膜新生血管的玻璃体内抗vegf可结晶蛋白药物

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2192131A1 (en) 1992-08-21 2010-06-02 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5408535A (en) 1993-09-07 1995-04-18 Miles Inc. Video test strip reader and method for evaluating test strips
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
NZ500078A (en) 1997-04-07 2001-10-26 Genentech Inc Humanized anti-VEGF antibodies and their use in inhibiting VEGF-induced angiogenesis in mammals
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
CA2405557C (en) 2000-04-12 2013-09-24 Human Genome Sciences, Inc. Albumin fusion proteins
KR100927261B1 (ko) 2001-01-17 2009-11-18 트루비온 파마슈티칼스, 인코포레이티드 결합 도메인-면역글로불린 융합 단백질
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
JP2005518805A (ja) 2002-03-01 2005-06-30 ボール・ホーティカルチャラル・カンパニー 花組織においてトランスジーンを発現させるためのｌｉｓプロモーター
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
JP2006515177A (ja) 2002-09-10 2006-05-25 ロランティス リミテッド Ｎｏｔｃｈリガンドタンパク質を含む医薬組成物及び医学的処置
AU2003286004A1 (en) 2002-11-08 2004-06-07 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
US20050043220A1 (en) 2002-11-08 2005-02-24 Guyer David R. Methods and compositions for treating macular degeneration
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
KR101025143B1 (ko) 2002-12-31 2011-04-01 넥타르 테라퓨틱스 가수분해상으로 안정한 말레이미드－종결 중합체
CN101412759A (zh) 2003-01-10 2009-04-22 埃博灵克斯股份有限公司 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
DK1639011T3 (da) 2003-06-30 2009-02-16 Domantis Ltd Pegylerede enkelt-domæne antistoffer (dAb)
AU2004268614C1 (en) 2003-08-27 2010-10-28 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
JP2007534631A (ja) 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
ES2352697T3 (es) 2003-11-07 2011-02-22 Ablynx N.V. Anticuerpos de dominio único de camelidae vhh dirigidos contra el receptor del factor de crecimiento epidérmico y usos de los mismos.
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
CA2583017A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
US20060134121A1 (en) 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
US20060134111A1 (en) 2004-12-17 2006-06-22 Genentech, Inc. Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
CN105085678B (zh) 2004-12-21 2019-05-07 阿斯利康公司 血管生成素-2的抗体及其应用
EP2172484A3 (en) * 2005-05-18 2010-05-19 Ablynx N.V. Serum albumin binding proteins
CN101213214B (zh) 2005-05-20 2014-06-25 埃博灵克斯股份有限公司 针对冯威勒布兰特因子的单一结构域vhh抗体
US8377398B2 (en) 2005-05-31 2013-02-19 The Board Of Regents Of The University Of Texas System Methods and compositions related to determination and use of white blood cell counts
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007028110A2 (en) 2005-09-01 2007-03-08 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
WO2007043109A1 (ja) 2005-09-30 2007-04-19 Fujitsu Limited 情報記憶装置
CA2633211A1 (en) 2005-12-15 2007-06-21 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
ES2400666T5 (es) 2005-12-16 2016-03-10 Regeneron Pharmaceuticals, Inc. Uso terapéutico de un antagonista de DII4 y un inhibidor de VEGF para inhibir el crecimiento tumoral
WO2007085815A2 (en) 2006-01-24 2007-08-02 Domantis Limited Ligands that bind il-4 and/or il-13
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
US7570881B2 (en) 2006-02-21 2009-08-04 Nokia Corporation Color balanced camera with a flash light unit
US20070269422A1 (en) * 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
AU2007319672B2 (en) 2006-06-06 2011-06-30 Genentech, Inc. Anti-DLL4 antibodies and methods using same
TW200817435A (en) 2006-06-06 2008-04-16 Genentech Inc Compositions and methods for modulating vascular development
CA2660235C (en) 2006-08-07 2015-09-22 Regeneron Pharmaceuticals, Inc. Therapeutic methods for treating vascular eye disorders with dll4 antagonists
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
WO2008028977A2 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
EP2086998B1 (en) 2006-10-11 2011-12-07 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and use thereof
CA2666974A1 (en) 2006-10-20 2008-11-06 Schering Corporation Fully human anti-vegf antibodies and methods of using
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
AU2008219216A1 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
US10259860B2 (en) 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
CA2681974C (en) 2007-03-29 2019-12-31 Genmab A/S Bispecific antibodies and methods for production thereof
GB0709333D0 (en) 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
EA200901494A1 (ru) 2007-06-06 2010-06-30 Домантис Лимитед Способы селекции протеазоустойчивых полипептидов
WO2008149147A2 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
EP2014680A1 (en) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
US8216571B2 (en) 2007-10-22 2012-07-10 Schering Corporation Fully human anti-VEGF antibodies and methods of using
KR101559599B1 (ko) 2007-11-26 2015-10-12 바이엘 인텔렉쳐 프로퍼티 게엠베하 항-메소텔린 항체 및 이의 용도
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
GB2470328A (en) 2008-03-05 2010-11-17 Ablynx Nv Novel antigen binding dimer complexes, methods of making and uses thereof
EP3692988A3 (en) 2008-03-18 2020-10-14 Genentech, Inc. Combinations of an anti-her2 antibody-drug conjugate and 5-fu, anti-vegf antibody, carboplatin or abt-869 and methods of use
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
AU2009254501B2 (en) 2008-06-05 2014-07-31 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
EP3216803B1 (en) 2008-06-25 2020-03-11 Novartis Ag Stable and soluble antibodies inhibiting vegf
WO2010027981A1 (en) 2008-09-03 2010-03-11 Genentech, Inc. Multispecific antibodies
US8192738B2 (en) 2008-09-19 2012-06-05 Medimmune, Llc Targeted antibodies directed to DLL4
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8858940B2 (en) 2008-12-10 2014-10-14 Ablynx N.V. Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
CA2749660C (en) 2009-01-13 2017-10-31 Fio Corporation A handheld diagnostic test device and method for use with an electronic device and a test cartridge in a rapid diagnostic test
WO2010124009A2 (en) 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
ES2534355T3 (es) 2009-06-17 2015-04-21 Abbvie Biotherapeutics Inc. Anticuerpos anti-VEGF y sus usos
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
UY32920A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
UY32917A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moléculas de unión a dll-4
RU2012140447A (ru) 2010-02-23 2014-03-27 Дженентек, Инк. Антиангиогенная терапия для лечения рака яичника
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
WO2012012499A1 (en) 2010-07-20 2012-01-26 Nurx Pharmaceuticals, Inc. Optical reader system
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
SG191712A1 (en) 2010-11-02 2013-08-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
TW201249459A (en) 2011-05-27 2012-12-16 Novartis Ag Method of treating vision disorders
KR102091293B1 (ko) 2011-09-23 2020-03-20 온코메드 파마슈티칼스, 인크. Vegf/dll4 결합제 및 그의 용도
MX350248B (es) * 2012-03-30 2017-08-31 Boehringer Ingelheim Int Moleculas de union a ang2.
US9292583B2 (en) * 2012-11-27 2016-03-22 Google Inc. Method of displaying search results

Also Published As

Publication number Publication date
NZ614249A (en) 2015-05-29
SI2694546T1 (sl) 2017-01-31
JP6023786B2 (ja) 2016-11-09
CO6801639A2 (es) 2013-11-29
MY171007A (en) 2019-09-23
MA34979B1 (fr) 2014-03-01
AU2017200237B2 (en) 2018-05-17
US20220017642A1 (en) 2022-01-20
JP6297657B2 (ja) 2018-03-20
US20130078248A1 (en) 2013-03-28
HUE030148T2 (en) 2017-04-28
US20170247475A1 (en) 2017-08-31
HRP20161689T1 (hr) 2017-02-24
BR112013025304A2 (pt) 2017-06-06
MX337543B (es) 2016-03-10
EP3144322A3 (en) 2017-05-31
JP2014515602A (ja) 2014-07-03
MX343440B (es) 2016-11-07
US11161916B2 (en) 2021-11-02
CL2013002623A1 (es) 2014-02-14
AU2012237234A1 (en) 2013-09-05
RS55361B1 (sr) 2017-03-31
CA2827817C (en) 2020-12-15
EA201600338A1 (ru) 2016-09-30
CN105820243A (zh) 2016-08-03
KR101907572B1 (ko) 2018-10-15
EP2694546B1 (en) 2016-09-21
AR085984A1 (es) 2013-11-13
US20200010569A1 (en) 2020-01-09
JP2017023152A (ja) 2017-02-02
DK2694546T3 (en) 2016-12-05
WO2012131078A1 (en) 2012-10-04
EA036746B1 (ru) 2020-12-16
CN103562222B (zh) 2016-04-06
MX2013010949A (es) 2014-06-06
PL2694546T3 (pl) 2017-03-31
IL227936B (en) 2018-06-28
LT2694546T (lt) 2016-11-10
AU2017200237A1 (en) 2017-02-02
PE20140448A1 (es) 2014-04-13
TN2013000390A1 (en) 2015-01-20
EP3144322A2 (en) 2017-03-22
UY33998A (es) 2012-09-28
HK1190412A1 (zh) 2014-07-04
ECSP13013001A (es) 2013-12-31
CN103562222A (zh) 2014-02-05
SG193561A1 (en) 2013-11-29
BR112013025304B1 (pt) 2022-10-11
SG10201602373TA (en) 2016-05-30
CA2827817A1 (en) 2012-10-04
US9527925B2 (en) 2016-12-27
AU2012237234B2 (en) 2016-10-20
CY1118339T1 (el) 2017-06-28
KR20140018317A (ko) 2014-02-12
US10414828B2 (en) 2019-09-17
EA025148B1 (ru) 2016-11-30
EP2694546A1 (en) 2014-02-12
IL227936A0 (en) 2013-09-30
HK1225400A1 (zh) 2017-09-08
ES2606302T3 (es) 2017-03-23
UA114707C2 (uk) 2017-07-25
EA201301108A1 (ru) 2014-03-31
AP2013007085A0 (en) 2013-08-31

Similar Documents

Publication Publication Date Title
HK1225400A1 (zh) 結合vegf和ang2的雙特異性結合分子
IL270223B (en) Molecules that specifically bind tdp–43
IL268336B (en) il-18 binding molecules
HRP20181355T1 (hr) Bispecifične molekule koje se vežu na antigen
HK1247938A1 (zh) 結合分子的生成
HUE039439T2 (hu) NGF aptamer és alkalmazása
AP2013007086A0 (en) Bispecific binding molecules binding to DII4 and Ang2
ZA201409540B (en) Binding molecules targeting pathogens